Jon D. Herrington, Pharm.D., BCPS, BCOP

Reportable Conflicts of Interests:  None

Disclosure of Financial Conflicts of Interest: None

Education:

Doctor of Pharmacy

St. Louis College of Pharmacy

St. Louis, MO

                                                         

Bachelors of Science in Pharmacy

St. Louis College of Pharmacy

St. Louis, MO

 

Post Graduate or Residency Training:           

Hematology/Oncology Specialty Residency

University of Kentucky Lucille P. Markey Cancer Center

 

Pharmacy Practice Residency

University of Kentucky Chandler Medical Center

 

Fellowship and Board Certifications:        

Board Certified Pharmacotherapy Specialist

Board of Pharmaceutical Specialties

 

Board Certified Oncology Pharmacy Specialist

Board of Pharmaceutical Specialties

 

Current Position or Practice Site:                   

Hematology/Oncology Clinical Pharmacy Specialist

Scott & White Memorial Hospital and Clinic

Temple, Texas

 

Associate Professor

Texas A&M Health Sciences Center

College of Medicine

Temple, Texas

 

Clinical Associate Professor

The University of Texas at Austin

College of Pharmacy

 

Professional Appointments:                                                  

Hematology / Oncology Specialty Residency Program Director

Scott & White Memorial Hospital

Temple, Texas

 

Past Positions and/or Appointments:                       

Assistant Professor

Texas A&M Health Science Center

Temple, Texas

Adjunct Assistant Professor
The University of Texas at Austin
College of Pharmacy

 

Professional Memberships:                                       

Hematology/Oncology Pharmacy Association, 2006-present

Texas Society of Health-System Pharmacists, 2005-present

American Society of Clinical Oncology, Affiliate Member, 2003-present

Scott & White CCOP / Southwest Oncology Group, 2002-present

American Society of Health-System Pharmacists, 2000-present

 

Publications:                                                    
Brown EN, Herrington JD. Review of the relationship between venous thromboembolism, malignancy and its treatment.  J Pharm Practice 2008;21:126-37.

 

Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.  Cancer 2008;112:2080-7.

 

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based higly active antiretroviral therapy in patients with human immunodeficiency virus.  Pharmacotherapy 2008;28:323-30.

 

Ziegler JA, Herrington JD.  Current and future options for the treatment of chemotherapy-induced anaemia. Expert Opin Investig Drugs 2006;15:1051-65.

 

Jaskiewicz AD, Herrington JD. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma (letter). Pharmacotherapy 2006;26:1205-6.

 

Herrington JD, Tran HT, Riggs M. Prospective Evaluation of Carboplatin AUC Dosing in Patients with a BMI ³27 or Cachexia. Cancer Chemother Pharmacol 2006;57:241-7.

 

Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome following bortezomib (Velcade) treatment in plasma cell leukemia. Pharmacotherapy 2005;25:1820-25.

 

Herrington JD. Darbepoetin versus epoetin (letter). Am J Health-Syst Pharm 2005;62:1556-7.

 

Mott FE, Esana A, Chakmakjian C, Herrington JD. Tumor lysis syndrome in solid tumors.  Supportive Cancer Therapy 2005;2:188-91.

 

Mott FE, Cable CT, Herrington JD, Marcus J, Griggs R, Ainslie M.  Phase II trial of celecoxib plus carboplatin and gemcitabine for first-line therapy in stage IIIB/IV non-small cell lung cancer - a negative study. Cancer Therapy 2005;3:237-42.

 

Herrington JD, Davidson S, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.  Am J Health-Sys Pharm 2005;62:54-62.

 

Gowan GM, Herrington JD, Simonetta AB. Methotrexate-induced toxic leukoencephalopathy. Pharmacotherapy 2002;22:1183-7.

 

Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis from cisplatin and etoposide. Pharmacotherapy 2002;22:1200-4.

 

Cool RM, Herrington JD.  Thalidomide in the management of relapsed and recurrent multiple myeloma.  Pharmacotherapy 2002;22:1019-28

 

Herrington JD, Figueroa JA, Kirstein MN, Zamboni WC, Stewart CF. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction.  Cancer Chemother Pharmacol 2001;47:89-93.

 

Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L, Riggs MW. Randomized comparison between oral ondansetron and granisetron for emetogenic chemotherapy. Pharmacotherapy 2000;20:1318-23.

 

Herrington JD, Di Nunno L, Rinehart JJ. Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis (letter). Ann Pharmacotherapy 1998;32:611-2.

 

Herrington AM, Herrington JD, Church C. Treatment options for cachexia. Nutr Clin Pract 1997;12:101-13.

 

Fleming DR, Ouseph R, Herrington JD. Hyperkalemia associated with cyclosporine (CsA) use in bone marrow transplantation. Bone Marrow Transplant 1997;19:289-91.

 

Herrington JD, Figueroa JA. Severe necrosis from paclitaxel extravasation.  Pharmacotherapy 1997;17:163-5.

 

Herrington JD, Gora-Harper ML, Salley RK. Chemical pleurodesis with doxycycline 1 g. Pharmacotherapy 1996;16:280-5.

 

Baker JL, Gosland MP, Herrington JD, Record KE.  Cytomegalovirus colitis following 5-fluorouracil and interferon-alpha therapy. Pharmacotherapy 1994;14:246-9.

 

Books and/or Chapters:

Herrington JD, Brown EN. Nausea, vomiting and anorexia. In: Tisdale JE, Miller DA, eds. Drug-induced Diseases: Prevention, Detection, and Management, 2^nd ed. Bethesda, MD: American Society of Health-System Pharmacists. Second edition is under review, June 2008.

 

Herrington JD, Labdi BA. Nausea, vomiting and anorexia. In: Tisdale JE, Miller DA, eds. Drug-induced Diseases: Prevention, Detection, and Management, 1^st ed. Bethesda, MD: American Society of Health-System Pharmacists. 2005;555-79.

 

Presentations (National, State and Local):

 

National
“Targets in the Molecular Pathophysiology of Cancer.”  Presented for ACPE continuing education credit program, Pharmacist’s Road Map to Targeted Therapies.  42^nd Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 4, 2007.

 

“What to Do With the Complicated Oncology Patient?”  Workshop presentation for the 3^rd Annual Hematology Oncology Pharmacy Association (HOPA) Conference, Denver, CO, June 15, 2007.

 

Carboplatin Dosing: Actual vs. Adjusted Parameters. Presentation at the 2006 American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 27, 2006.

 

State Level
New Growth in Oncology.  Presented at the TSHP 58^th Annual Seminar for ACPE credit, Galveston, TX. April 2, 2006.

 

Treatment of Chemotherapy-Induced Anemia: What the Data Says.  Presented at the Texas Society of Health-System Pharmacists 57^th Annual Seminar for ACPE credit. Austin, TX, April 10, 2005

Local Level
Update on the Guidelines for the Treatment of Community-Acquired Pneumonia.  Presented for ACPE credit to the Heart of Texas Hospital Pharmacy group.  Waco, TX, February 20, 2003.

 

Antibiotics for the Treatment of Lower Respiratory Tract Infections. Presented at “Drug Therapy 1999: Clinical Review and Pearls” for continuing education for physicians, nurses, and pharmacists. Mayborn Convention Center. Temple, TX, August 28, 1999.

 

Medications for Post-Herpetic Neuralgia.  Presented at the “1999-Advanced Practice Nursing Symposium”, Mayborn Convention Center. Temple, TX. January 27, 1999.

 

The Use of Rituximab against Lymphoma. Presented to the Heart of Texas Oncology Nursing Society for Continuing Education Credit. Temple, TX, March 12, 1998.

 

Managing Pediatric Pain & Symptoms in the Home Setting.  Presented with Lawrence Frankel, M.D. at the conference, “Caring for Children: End-of-Life Palliative and Hospice Solutions.  Sponsored by Scott & White, Texas Non-Profit Hospice Alliance, and Texas A&M Science Center, College of Medicine.  Presented for Continuing Education Credit for physicians, nurses, and social workers.  Marriott at the Capitol, Austin, Texas. February 27, 1998.

 

Pharmacotherapeutics. Presented at the conference, “The Light at the End of Tunnel is Not a Train: Bone Marrow and/or Peripheral Blood Stem Cell Transplantation.” Sponsored by Oncology Nursing Society, Heart of Texas Chapter and Scott & White Memorial Hospital. Presented for Continuing Education Credit. Scott & White. Temple, TX, January 30, 1998.

 

Overview of Colony Stimulating Factors. Presented for Continuing Education Credit for the Bluegrass Pharmacists' Association. Lexington, KY, March 20, 1994.

 

Biologic Response Modifiers: The Next Frontier; Hematopoietic Growth Factors.  Presented for Continuing Education Credit for nurses and pharmacists, St. Joseph's Hospital, Lexington, KY, September 1, 1993.

 

A Double-Blind Comparison of the Efficacy of Two Dose Regimens of Oral Granisetron in Preventing Acute Emesis in Patients Receiving Moderately Emetogenic Chemotherapy; presented at the Great Lakes Residency Conference, Lexington, KY, April 1993.

 

(Last updated: 2/9/2009)